ID
12959
Description
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression; ODM derived from: https://clinicaltrials.gov/show/NCT00033514
Link
https://clinicaltrials.gov/show/NCT00033514
Keywords
Versions (1)
- 1/7/16 1/7/16 -
Uploaded on
January 7, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Breast Cancer NCT00033514
Eligibility Breast Cancer NCT00033514
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Similar models
Eligibility Breast Cancer NCT00033514
- StudyEvent: Eligibility
C0079399 (UMLS CUI [2])
C0027627 (UMLS CUI [1,2])
C0242957 (UMLS CUI [1,2])
C0860888 (UMLS CUI [2])
C0338204 (UMLS CUI [2])